Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
With Lumoxiti confirmed as commercially unviable monalizumab fails its phase 3 trial in head and neck cancer.
Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
The company believes its new combination technology can make insulin injections a thing of the past.